vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Reddit, Inc. (RDDT). Click either name above to swap in a different company.

Reddit, Inc. is the larger business by last-quarter revenue ($663.0M vs $406.6M, roughly 1.6× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 30.8%, a 29.7% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 69.0%). Reddit, Inc. produced more free cash flow last quarter ($311.0M vs $291.2M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 53.6%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Reddit is an American proprietary social news aggregation and forum social media platform. Registered users submit content to the site such as links, text posts, images, and videos, which are then voted up or down by other members. Posts are organized by subject into user-created boards called "subreddits". Submissions with more upvotes appear towards the top of their subreddit and, if they receive enough upvotes, ultimately on the site's front page. Reddit administrators moderate the communi...

BCRX vs RDDT — Head-to-Head

Bigger by revenue
RDDT
RDDT
1.6× larger
RDDT
$663.0M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+140.1% gap
BCRX
209.1%
69.0%
RDDT
Higher net margin
BCRX
BCRX
29.7% more per $
BCRX
60.5%
30.8%
RDDT
More free cash flow
RDDT
RDDT
$19.8M more FCF
RDDT
$311.0M
$291.2M
BCRX
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
53.6%
RDDT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
RDDT
RDDT
Revenue
$406.6M
$663.0M
Net Profit
$245.8M
$204.0M
Gross Margin
97.7%
100.0%
Operating Margin
64.0%
0.0%
Net Margin
60.5%
30.8%
Revenue YoY
209.1%
69.0%
Net Profit YoY
1017.5%
680.0%
EPS (diluted)
$1.13
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
RDDT
RDDT
Q1 26
$663.0M
Q4 25
$406.6M
$725.6M
Q3 25
$159.4M
$584.9M
Q2 25
$163.4M
$499.6M
Q1 25
$145.5M
$392.4M
Q4 24
$131.5M
$427.7M
Q3 24
$117.1M
$348.4M
Q2 24
$109.3M
$281.2M
Net Profit
BCRX
BCRX
RDDT
RDDT
Q1 26
$204.0M
Q4 25
$245.8M
$251.6M
Q3 25
$12.9M
$162.7M
Q2 25
$5.1M
$89.3M
Q1 25
$32.0K
$26.2M
Q4 24
$-26.8M
$71.0M
Q3 24
$-14.0M
$29.9M
Q2 24
$-12.7M
$-10.1M
Gross Margin
BCRX
BCRX
RDDT
RDDT
Q1 26
100.0%
Q4 25
97.7%
91.9%
Q3 25
98.6%
91.0%
Q2 25
98.3%
90.8%
Q1 25
96.9%
90.5%
Q4 24
95.4%
92.6%
Q3 24
97.3%
90.1%
Q2 24
98.4%
89.5%
Operating Margin
BCRX
BCRX
RDDT
RDDT
Q1 26
0.0%
Q4 25
64.0%
31.9%
Q3 25
18.6%
23.7%
Q2 25
18.2%
13.6%
Q1 25
14.6%
1.0%
Q4 24
-3.4%
12.4%
Q3 24
6.6%
2.0%
Q2 24
8.0%
-11.0%
Net Margin
BCRX
BCRX
RDDT
RDDT
Q1 26
30.8%
Q4 25
60.5%
34.7%
Q3 25
8.1%
27.8%
Q2 25
3.1%
17.9%
Q1 25
0.0%
6.7%
Q4 24
-20.4%
16.6%
Q3 24
-12.0%
8.6%
Q2 24
-11.6%
-3.6%
EPS (diluted)
BCRX
BCRX
RDDT
RDDT
Q1 26
$1.01
Q4 25
$1.13
$1.24
Q3 25
$0.06
$0.80
Q2 25
$0.02
$0.45
Q1 25
$0.00
$0.13
Q4 24
$-0.13
$4.76
Q3 24
$-0.07
$0.16
Q2 24
$-0.06
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
RDDT
RDDT
Cash + ST InvestmentsLiquidity on hand
$274.7M
$1.4B
Total DebtLower is stronger
Stockholders' EquityBook value
$-119.2M
$3.2B
Total Assets
$514.2M
$3.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
RDDT
RDDT
Q1 26
$1.4B
Q4 25
$274.7M
$953.6M
Q3 25
$212.9M
$911.7M
Q2 25
$260.0M
$734.1M
Q1 25
$295.1M
$635.7M
Q4 24
$320.9M
$562.1M
Q3 24
$96.8M
$515.9M
Q2 24
$78.4M
$468.0M
Stockholders' Equity
BCRX
BCRX
RDDT
RDDT
Q1 26
$3.2B
Q4 25
$-119.2M
$2.9B
Q3 25
$-387.9M
$2.6B
Q2 25
$-421.6M
$2.4B
Q1 25
$-451.9M
$2.2B
Q4 24
$-475.9M
$2.1B
Q3 24
$-468.6M
$2.0B
Q2 24
$-475.6M
$1.9B
Total Assets
BCRX
BCRX
RDDT
RDDT
Q1 26
$3.5B
Q4 25
$514.2M
$3.2B
Q3 25
$446.4M
$2.9B
Q2 25
$457.2M
$2.6B
Q1 25
$480.0M
$2.4B
Q4 24
$490.4M
$2.3B
Q3 24
$491.3M
$2.2B
Q2 24
$472.4M
$2.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
RDDT
RDDT
Operating Cash FlowLast quarter
$292.0M
Free Cash FlowOCF − Capex
$291.2M
$311.0M
FCF MarginFCF / Revenue
71.6%
46.9%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M
$868.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
RDDT
RDDT
Q1 26
Q4 25
$292.0M
$266.8M
Q3 25
$41.6M
$185.2M
Q2 25
$41.3M
$111.3M
Q1 25
$-27.5M
$127.6M
Q4 24
$-5.2M
$90.0M
Q3 24
$8.2M
$71.6M
Q2 24
$-1.4M
$28.4M
Free Cash Flow
BCRX
BCRX
RDDT
RDDT
Q1 26
$311.0M
Q4 25
$291.2M
$263.6M
Q3 25
$40.3M
$183.1M
Q2 25
$41.1M
$110.8M
Q1 25
$-27.7M
$126.6M
Q4 24
$-5.9M
$89.2M
Q3 24
$8.2M
$70.3M
Q2 24
$-1.5M
$27.2M
FCF Margin
BCRX
BCRX
RDDT
RDDT
Q1 26
46.9%
Q4 25
71.6%
36.3%
Q3 25
25.3%
31.3%
Q2 25
25.2%
22.2%
Q1 25
-19.0%
32.3%
Q4 24
-4.5%
20.8%
Q3 24
7.0%
20.2%
Q2 24
-1.4%
9.7%
Capex Intensity
BCRX
BCRX
RDDT
RDDT
Q1 26
Q4 25
0.2%
0.4%
Q3 25
0.8%
0.4%
Q2 25
0.1%
0.1%
Q1 25
0.1%
0.2%
Q4 24
0.5%
0.2%
Q3 24
0.1%
0.4%
Q2 24
0.1%
0.4%
Cash Conversion
BCRX
BCRX
RDDT
RDDT
Q1 26
Q4 25
1.19×
1.06×
Q3 25
3.23×
1.14×
Q2 25
8.12×
1.25×
Q1 25
-859.91×
4.88×
Q4 24
1.27×
Q3 24
2.40×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons